286 related articles for article (PubMed ID: 27814458)
1. Test-retest reproducibility of extrastriatal binding with
Matsuoka K; Yasuno F; Shinkai T; Miyasaka T; Takahashi M; Kiuchi K; Kosaka J; Inoue M; Kichikawa K; Hasegawa M; Kishimoto T
Psychiatry Res Neuroimaging; 2016 Dec; 258():10-15. PubMed ID: 27814458
[No Abstract] [Full Text] [Related]
2. Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects.
Koopman KE; la Fleur SE; Fliers E; Serlie MJ; Booij J
J Nucl Med; 2012 Jul; 53(7):1087-90. PubMed ID: 22627000
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Extrastriatal
Joling M; Vriend C; van den Heuvel OA; Raijmakers PGHM; Jones PA; Berendse HW; Booij J
J Nucl Med; 2017 Jul; 58(7):1117-1123. PubMed ID: 27856628
[No Abstract] [Full Text] [Related]
4. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
[TBL] [Abstract][Full Text] [Related]
5. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
[TBL] [Abstract][Full Text] [Related]
6. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.
Ziebell M; Holm-Hansen S; Thomsen G; Wagner A; Jensen P; Pinborg LH; Knudsen GM
J Nucl Med; 2010 Dec; 51(12):1885-91. PubMed ID: 21078806
[TBL] [Abstract][Full Text] [Related]
7. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects.
Booij J; de Jong J; de Bruin K; Knol R; de Win MM; van Eck-Smit BL
J Nucl Med; 2007 Mar; 48(3):359-66. PubMed ID: 17332612
[TBL] [Abstract][Full Text] [Related]
8. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An
van der Zande JJ; Joling M; Happach IG; Vriend C; Scheltens P; Booij J; Lemstra AW
Neuroimage Clin; 2020; 25():102062. PubMed ID: 31790878
[TBL] [Abstract][Full Text] [Related]
9. Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation.
Greco A; Zannetti A; Pappatà S; Albanese S; Coda AR; Ragucci M; Nardelli A; Brunetti A; Cuocolo A; Salvatore M
Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):112-117. PubMed ID: 26329495
[TBL] [Abstract][Full Text] [Related]
10. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
[TBL] [Abstract][Full Text] [Related]
11. Preserved Extrastriatal
Nicastro N; Burkhard PR; Garibotto V
Mol Imaging Biol; 2020 Dec; 22(6):1592-1599. PubMed ID: 32468408
[TBL] [Abstract][Full Text] [Related]
12. [Striatal dopamine transporter levels in patients with REM sleep behavior disorder: assessment with 123I-FP-CIT SPECT].
Mossa EP; Niccoli Asabella A; Iuele F; Stabile Ianora AA; Giganti M; Rubini G
Recenti Prog Med; 2012 Nov; 103(11):500-4. PubMed ID: 23096739
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT.
Nikolaus S; Wirrwar A; Antke C; Arkian S; Schramm N; Müller HW; Larisch R
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):308-13. PubMed ID: 15791440
[TBL] [Abstract][Full Text] [Related]
14. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
[TBL] [Abstract][Full Text] [Related]
15. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
[TBL] [Abstract][Full Text] [Related]
16. Additional Role of Midbrain F-18 FP-CIT Uptake on PET in Evaluation of Essential Tremor and Parkinsonism.
Lee H; Sung YH; Hwang KH
Curr Med Imaging; 2023; 19(9):1041-1051. PubMed ID: 36734891
[TBL] [Abstract][Full Text] [Related]
17. Dorsal-to-Ventral Shift in Midbrain Dopaminergic Projections and Increased Thalamic/Raphe Serotonergic Function in Early Parkinson Disease.
Joutsa J; Johansson J; Seppänen M; Noponen T; Kaasinen V
J Nucl Med; 2015 Jul; 56(7):1036-41. PubMed ID: 25952735
[TBL] [Abstract][Full Text] [Related]
18. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
[TBL] [Abstract][Full Text] [Related]
19. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
[TBL] [Abstract][Full Text] [Related]
20. Serotonin transporter binding and anxiety symptoms in Parkinson's disease.
Joling M; van den Heuvel OA; Berendse HW; Booij J; Vriend C
J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):89-94. PubMed ID: 28899958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
